This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I51 (complications and ill-defined descriptions of heart disease) | Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Ventricular septal defect (acquired, I51.0), rupture of chordae tendineae (I51.1), rupture of papillary muscle (I51.2), intracardiac thrombosis (I51.3), myocarditis, unspecified (I51.4), myocardial degeneration (I51.5), cardiomegaly (I51.7), Takotsubo syndrome (I51.81), heart disease, unspecified (I51.9) |
| C. Adult onset | Takotsubo syndrome occurs predominantly in postmenopausal women aged 60 and over. Mechanical complications after myocardial infarction (papillary muscle rupture, ventricular septal defect) occur within days after acute myocardial infarction. |
| 1. History | Takotsubo syndrome first described in Japan in the 1990s. Mechanical complications after myocardial infarction were more common in the pre-reperfusion era but still occur in patients with delayed reperfusion. |
| 2. Causes | Post-infarction necrosis (mechanical complications), ischemia other than acute myocardial infarction, emotional/physical stress (Takotsubo), hypertension, tachycardia, toxicity (myocardial degeneration), myocarditis. |
| 3. Genetics | ADRB2 (beta-2 receptor) polymorphisms and ADRA2C variants have been reported in Takotsubo. TTN and LMNA variants associated with familial cardiomyopathy are associated with myocardial degeneration. |
| 4. General epidemiology | Takotsubo syndrome accounts for about 1–3% of ACS-like cases. More than 90% are women, especially in their 60s–70s. The incidence of mechanical complications after myocardial infarction has fallen markedly since the reperfusion era (<1%). |
| 5. Pathophysiology | Takotsubo: catecholamine excess → sympathetic stimulation → apical stunning/contractile abnormality. Mechanical complications: acute myocardial necrosis → increased tissue fragility → rupture. |
| 6. Symptoms | Takotsubo: chest pain, dyspnea (ACS-like). Papillary muscle/chordal rupture: sudden severe pulmonary edema. Ventricular septal defect: heart failure with a heart murmur. Intracardiac thrombus: embolic complications. |
| 7. Signs | Takotsubo: apical ballooning on echocardiography. Papillary muscle rupture: holosystolic murmur, acute pulmonary edema. Acquired VSD: systolic murmur, right heart failure. |
| 8. Screening | In patients with acute chest pain, initial differentiation of ACS and Takotsubo with troponin and ECG. With abrupt hemodynamic deterioration after myocardial infarction, immediate echocardiography to evaluate mechanical complications. |
| 9. Diagnosis | Takotsubo: InterTAK diagnostic criteria, echocardiography, coronary angiography (normal or non-obstructive). Mechanical complications: echocardiography, Doppler, urgent cardiac catheterization. |
| 10. Treatment | Takotsubo: supportive (symptomatic) care. Mechanical complications: immediate surgical repair or percutaneous procedure. Intracardiac thrombus: anticoagulation. Myocardial degeneration: principles of heart failure treatment. |
| 11. Prognosis | Takotsubo: cardiac function mostly recovers within 3–6 months. In-hospital mortality about 2–5%. Mechanical complications: fatal without immediate surgical repair. Intracardiac thrombus: embolism preventable with anticoagulation. |
| 12. Prevention | Prevention of mechanical complications with early reperfusion of myocardial infarction (PPCI). Managing severe emotional stress and cautious use of risky drugs (catecholamine injections) help prevent Takotsubo. |
| 13. References | Takotsubo Syndrome: A Review of Presentation, Diagnosis and Management (2022) … and 9 other papers |
The ICD-10 I51 category is a broad classification that includes cardiac complications and ill-defined heart diseases not more clearly classified under other codes such as myocardial infarction, valvular disease and cardiomyopathy. The most recently described clinical entity in this category is Takotsubo syndrome (TTS); in 1990 Satoh and Dote of Hiroshima City Hospital in Japan first described cases showing an apical ballooning shape on left ventriculography resembling a Japanese octopus trap pot (takotsubo). This distinctive contractile abnormality pattern, its reversibility and its association with preceding emotional stress drew attention, and it also came to be called "broken heart syndrome" or "stress cardiomyopathy".
Takotsubo syndrome began to receive serious attention in Western medicine in 2001, when Tsuchihashi et al. reported 88 cases in a multicenter study in Japan. As cases were subsequently recognized worldwide, Takotsubo syndrome was established as an independent clinical entity with symptoms similar to ACS but without coronary occlusion. In 2018 the European Society of Cardiology (ESC) published diagnostic criteria (InterTAK criteria) and management guidelines for Takotsubo syndrome.
The history of mechanical complications after myocardial infarction (papillary muscle rupture, ventricular septal defect, free wall rupture) shows the flip side of advances in myocardial infarction treatment. In the pre-reperfusion era (before the 1990s), the incidence of mechanical complications after acute myocardial infarction was considerable (ventricular septal defect about 1–2%, papillary muscle rupture about 1%). Since primary percutaneous coronary intervention (PPCI) became standard in the 1990s, the incidence of these complications has fallen markedly, but they still occur when reperfusion is delayed or initial treatment is not received. These complications are cardiac emergencies with very high mortality without immediate surgical repair.
The various cardiac complications and ill-defined heart diseases in the I51 category also have diverse causes.
The most common triggers of Takotsubo syndrome (I51.81) are emotional stress (heartbreak, loss, fear, anger — "emotional Takotsubo") and physical stress (surgery, trauma, pneumonia, stroke — "physical Takotsubo"). The prognosis of physical stress–triggered Takotsubo is notably worse. Direct administration of catecholamines (epinephrine, dopamine) and catecholamine excess due to pheochromocytoma are also causes. Takotsubo syndrome also occurs not infrequently in neurological diseases (subarachnoid hemorrhage, stroke), suggesting the importance of brain-heart interaction.
The common cause of mechanical complications after myocardial infarction is tissue fragility due to acute myocardial necrosis. Papillary muscle rupture occurs mainly in inferior myocardial infarction (involving the posterolateral papillary muscle), and acquired ventricular septal defect (VSD) in anterior myocardial infarction (anteroseptal region). Rupture of the chordae tendineae occurs not only with acute myocardial infarction but also with infective endocarditis and myxomatous valve degeneration. Intracardiac thrombus (I51.3) forms from blood stasis in heart failure (hypokinetic ventricular walls), atrial fibrillation and hypokinetic segments after myocardial infarction. Myocardial degeneration (I51.5) refers to degenerative changes of cardiomyocytes due to ischemia, toxicity (alcohol, anticancer drugs), nutritional deficiency and the like.
Research on genetic factors in I51 category diseases is particularly active for Takotsubo syndrome. A genetic predisposition is presumed to contribute to the development of Takotsubo syndrome, but no definite gene variant has yet been established. There are reports that polymorphisms in the ADRB2 (β2-adrenergic receptor) gene related to the sympathetic nervous system response — particularly the Arg16Gly and Gln27Glu variants — are associated with the risk of Takotsubo syndrome. In addition, ADRA2C (α2C-adrenergic receptor) variants are also involved in regulating sympathetic activity and may contribute to excessive catecholamine release during the stress response.
A genetic basis is sometimes identified in diseases with a phenotype similar to Takotsubo. In Takotsubo-like cardiomyopathy due to pheochromocytoma, pheochromocytoma-related genes (RET, VHL, SDHB/C/D, NF1) are involved. Genetic causes associated with myocardial degeneration and cardiomegaly include hypertrophic cardiomyopathy (MYH7, MYBPC3), laminopathy (LMNA), amyloidosis (TTR, APOA1) and glycogen storage disease (PRKAG2, GAA in Pompe disease), which may initially be classified as cardiomegaly (I51.7) or ill-defined heart disease (I51.9). For this reason, genetic testing to exclude inherited cardiomyopathy is considered in young patients or patients with a family history who have myocardial degeneration or cardiomegaly.
Takotsubo syndrome is diagnosed in about 1–3% of patients with suspected ACS, and the diagnosis rate is increasing as awareness grows. About 90% of patients are women, and most of them (about 80–85%) are postmenopausal. The 60s–70s are the age group with the highest incidence. Male Takotsubo patients are relatively rare but are reported to have a worse prognosis. More than about 100,000 cases of Takotsubo syndrome are diagnosed worldwide each year, and the actual incidence is estimated to be higher.
The incidence of mechanical complications after myocardial infarction has fallen greatly since the introduction of primary PCI. The current incidence after myocardial infarction is reported at about 0.2–0.3% for acquired VSD, about 0.02–0.5% for papillary muscle rupture and about 0.2–0.7% for free wall rupture. However, when these complications occur, mortality without surgical repair is very high (untreated mortality of acquired VSD 50–90%), so they remain an important clinical problem. As for intracardiac thrombus, ventricular thrombus occurs in about 5–15% after myocardial infarction, and left atrial appendage thrombus in about 10–15% in atrial fibrillation.
Myocardial injury due to catecholamine excess is central to the pathophysiology of Takotsubo syndrome. During emotional or physical stress, large amounts of epinephrine and norepinephrine are released from the adrenal medulla, overactivating cardiac beta-2 receptors. Because beta-2 receptors are more densely distributed at the apex (ventricular tip), the apex is more severely affected by catecholamine excess. As a result, a characteristic pattern forms in which apical contractile function declines (apical ballooning) while the base is hypercontractile (hyperkinesis). In addition, catecholamine-induced coronary spasm, microvascular dysfunction and direct myocardial toxicity also contribute to the mechanism.
The mechanism of mechanical complications after myocardial infarction is structural myocardial damage due to acute myocardial necrosis. When a papillary muscle or chordae are weakened by ischemic necrosis, excessive tension during contraction causes rupture, resulting in acute severe mitral regurgitation. Ventricular septal defect results from rupture of the septum after anteroseptal myocardial necrosis, forming a left-to-right ventricular shunt. Intracardiac thrombus results from the combined action of blood stasis due to reduced ventricular motion, exposure of tissue factor due to endothelial injury, and a hypercoagulable state (Virchow's triad).
The main symptoms of Takotsubo syndrome closely resemble those of acute coronary syndrome (ACS), making differentiation difficult. Chest pain (about 75%) and dyspnea (about 50%) are the most common symptoms, and syncope, nausea, and vomiting may also occur. The chest pain is usually a dull pressure or tightness and is nearly indistinguishable from ACS chest pain. Emotional stress (bereavement, separation, fear, anger) or physical stress (surgery, infection, neurological disease) preceding symptom onset strongly suggests Takotsubo.
In post-infarction papillary muscle rupture, sudden severe dyspnea and pulmonary edema are the main symptoms, appearing within 2–7 days after myocardial infarction together with rapid hemodynamic deterioration. In acquired VSD, rapid heart failure develops together with a new systolic murmur. The most serious complication of intracardiac thrombus is embolism from thrombus detachment, which can cause stroke, lower limb ischemia, renal infarction, and other events.
In Takotsubo syndrome, cardiac auscultation may be nonspecific, but an S3 gallop and systolic murmur may be heard with severe left ventricular dysfunction. The most characteristic sign is apical ballooning on echocardiography, in which the apex balloons out during systole while the base is hypercontractile. The extent of this finding does not match a coronary artery distribution, which helps differentiate it from ACS.
The characteristic sign of acquired VSD is a new harsh systolic murmur (best heard over the precordium and lower sternal border), reflecting a left-to-right shunt. Signs of right heart failure (elevated JVP, hepatomegaly, lower limb edema) appear rapidly. The characteristic sign of papillary muscle rupture is sudden pulmonary edema with a new holosystolic murmur (radiating to the apex and axilla). Intracardiac thrombus often shows no specific findings on physical examination, but echocardiography reveals an echogenic thrombus at the ventricular apex or left atrial appendage.
Screening for Takotsubo syndrome is mainly performed in patients with suspected ACS. In patients with chest pain and ST elevation or T-wave inversion, the possibility of Takotsubo should always be considered before coronary angiography. When ACS-like symptoms occur in postmenopausal women with specific stress triggers (bereavement, surgery, severe infection, etc.), Takotsubo should be actively considered.
Screening for mechanical complications in patients with myocardial infarction is performed through ECG and hemodynamic monitoring during hospitalization. Sudden hemodynamic deterioration, a new murmur, or rapid pulmonary edema after myocardial infarction requires immediate echocardiography. Because patients with ventricular dysfunction are at high risk of intracardiac thrombus, thrombus is actively checked with regular echocardiography, and cardiac MRI when needed, after myocardial infarction and in patients with heart failure.
Takotsubo syndrome is diagnosed using the InterTAK diagnostic criteria published by the ESC in 2018. Major criteria: (1) transient left ventricular dysfunction (apical ballooning or other variants), (2) wall motion abnormality not matching a coronary artery distribution, (3) absent or minimal coronary artery occlusion or angiographic findings, (4) ECG changes (ST elevation or inversion, QTc prolongation), (5) mild elevation of cardiac enzymes. Apical ballooning, midsegment wall motion abnormality, and a normal or hypercontractile base are characteristic on echocardiography. Cardiac MRI evaluates myocardial inflammation and edema and, by confirming the absence of scar, helps differentiate it from myocardial infarction.
Acquired VSD is confirmed by Doppler echocardiography (color Doppler visualization of the left-to-right shunt) and cardiac catheterization (oxygen saturation step-up). Papillary muscle rupture is confirmed on echocardiography by rupture of the papillary muscle or chordae tendineae together with acute severe mitral regurgitation. Intracardiac thrombus is evaluated for location, size, and mobility with echocardiography and, when needed, cardiac CT or MRI.
Acute-phase treatment of Takotsubo syndrome is mainly symptomatic supportive therapy. In hemodynamically stable patients, beta-blockers, ACE inhibitors, or ARBs are used to control symptoms and promote recovery of cardiac function. In acute heart failure, diuretics and blood pressure control are needed. An important caution is that catecholamine-based vasopressors (dopamine, epinephrine) can worsen symptoms in Takotsubo patients and should be avoided where possible; instead, phenylephrine, norepinephrine, or mechanical circulatory support (IABP, Impella) should be considered first. Anticoagulation is needed when there is intraventricular flow disturbance or a high risk of thrombus formation.
Mechanical complications after myocardial infarction are, in principle, managed with emergency surgical treatment. In acquired VSD, surgical VSD repair is the standard, and in hemodynamically unstable cases surgery is performed after percutaneous mechanical circulatory support. Percutaneous VSD closure (Amplatzer occluder) is also possible in some patients. In papillary muscle rupture, mitral valve repair or replacement is performed urgently. Intracardiac thrombus is treated by starting immediate anticoagulation with unfractionated heparin or low-molecular-weight heparin, followed by warfarin (target INR 2–3) or a DOAC for 3–6 months.
The prognosis of Takotsubo syndrome is mostly favorable. In about 95% of patients, left ventricular function recovers fully or nearly to normal within 3–6 months. However, acute-phase mortality is about 2–5%, so it cannot be regarded as a purely benign disease, and in-hospital mortality is particularly higher in Takotsubo triggered by physical stress. Complications such as cardiogenic shock (about 5–10%), ventricular tachycardia/ventricular fibrillation (about 5%), and left ventricular thrombus formation (about 2–5%) can occur in the acute phase. The recurrence rate is about 5–10% (5-year cumulative), and the presentation pattern may change upon recurrence. Studies have shown that, in the long term, patients with Takotsubo syndrome have a higher risk of cardiovascular death and major cardiovascular events than the general population.
The prognosis of mechanical complications after myocardial infarction depends on whether treatment is immediate. In acquired VSD, 30-day mortality with surgery is still high at about 30–50%, but because untreated mortality within 1 week approaches nearly 100%, the benefit of surgical treatment is clear. The 30-day mortality after surgical repair of papillary muscle rupture is about 20–40%.
Clear evidence for the prevention of Takotsubo syndrome is currently lacking, but several principles apply. Avoiding extreme emotional stress and stress management (meditation, psychotherapy) may lower the risk of recurrence. Early management of physical illness (infection, pain, surgical stress), a potential trigger of Takotsubo syndrome, is also important. Direct catecholamine administration (epinephrine injection, and sympathomimetic drugs such as cocaine and methamphetamine) carries a risk of triggering Takotsubo, so caution is needed in vulnerable patients.
Early reperfusion therapy (PPCI) is the most effective prevention of mechanical complications after myocardial infarction. Arriving at the hospital as soon as possible after the onset of acute myocardial infarction symptoms and receiving primary PCI is the key to preventing mechanical complications. During hospitalization, appropriate antiplatelet therapy, anticoagulation, and early initiation of ACE inhibitors and beta-blockers when ventricular function is reduced after myocardial infarction suppress ventricular remodeling and prevent cardiac hypertrophy and intracardiac thrombus formation.
Assad J, Femia G, Pender P, Badie T, Rajaratnam R. Takotsubo Syndrome: A Review of Presentation, Diagnosis and Management. Clin Med Insights Cardiol. 2022;16:11795468211065782. DOI: 10.1177/11795468211065782. PMID: 35140531.
Lyon AR, Bossone E, Schneider B, et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18(1):8-27. DOI: 10.1002/ejhf.424. PMID: 26548803.
Ghadri JR, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018;39(22):2032-2046. DOI: 10.1093/eurheartj/ehy076. PMID: 29850871.
Templin C, Ghadri JR, Diekmann J, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med. 2015;373(10):929-938. DOI: 10.1056/NEJMoa1406761. PMID: 26332547.
Dalugama C, Gawarammana IB. Cardiac rupture as a life-threatening outcome of Takotsubo syndrome: A systematic review. Int J Cardiol. 2024;413:132413. DOI: 10.1016/j.ijcard.2024.132413. PMID: 38986724.
Stiermaier T, Moeller C, Oehler K, et al. Long-term excess mortality in takotsubo cardiomyopathy: predictors, causes and clinical consequences. Eur J Heart Fail. 2016;18(6):650-656. DOI: 10.1002/ejhf.494. PMID: 26848911.
Birnbaum Y, Fishbein MC, Blanche C, Siegel RJ. Ventricular septal rupture after acute myocardial infarction. N Engl J Med. 2002;347(18):1426-1432. DOI: 10.1056/NEJMra020228. PMID: 12409546.
Keeley EC, de Lemos JA. Free wall rupture in the elderly: deleterious effect of fibrinolytic therapy on the ageing heart. Eur Heart J. 2005;26(17):1693-1694. DOI: 10.1093/eurheartj/ehi391. PMID: 16030073.
Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075-3123. DOI: 10.1093/eurheartj/ehv319. PMID: 26320109.
Atar S, Luo H, Siegel RJ. Intracardiac thrombus. Heart. 2006;92(11):1539. DOI: 10.1136/hrt.2006.091363. PMID: 17041121.